{"protocolSection":{"identificationModule":{"nctId":"NCT01464788","orgStudyIdInfo":{"id":"HSC-MS-11-0464"},"organization":{"fullName":"The University of Texas Health Science Center, Houston","class":"OTHER"},"briefTitle":"Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke","officialTitle":"ARTSS-2: A Pilot, Phase 2b, Randomized, Multi-center Trial of Argatroban in Combination With Recombinant Tissue Plasminogen Activator for Acute Stroke","acronym":"ARTSS-2"},"statusModule":{"statusVerifiedDate":"2017-03","overallStatus":"TERMINATED","whyStopped":"The study was halted prematurely at 90 of 105 planned patients due to the beneficial results of embolectomy clinical trials.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-10"},"primaryCompletionDateStruct":{"date":"2015-06-11","type":"ACTUAL"},"completionDateStruct":{"date":"2015-06-11","type":"ACTUAL"},"studyFirstSubmitDate":"2011-11-01","studyFirstSubmitQcDate":"2011-11-01","studyFirstPostDateStruct":{"date":"2011-11-04","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-01-26","resultsFirstSubmitQcDate":"2017-03-31","resultsFirstPostDateStruct":{"date":"2017-05-11","type":"ACTUAL"},"lastUpdateSubmitDate":"2017-03-31","lastUpdatePostDateStruct":{"date":"2017-05-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Andrew D. Barreto, MD","investigatorTitle":"Assistant Professor of Neurology","investigatorAffiliation":"The University of Texas Health Science Center, Houston"},"leadSponsor":{"name":"Andrew D. Barreto, MD","class":"OTHER"},"collaborators":[{"name":"The University of Texas Health Science Center, Houston","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Randomized controlled clinical trial to estimate overall treatment benefit (improvement in disability) among stroke patients treated with rt-PA who are randomized to also receive either low-dose Argatroban, high-dose Argatroban or neither.","detailedDescription":"Recombinant tissue plasminogen activator (rt-PA), the only proven treatment for acute ischemic stroke, fails to reperfuse brain in most patients with large thrombi. In our Phase 2a low-dose safety study (n=65), the two drugs appeared safe when delivered concomitantly and recanalization rates were greater than historical controls. This study will provide evidence-based hypotheses and data needed to design a larger definitive trial.\n\nThe purpose of this trial is to estimate overall treatment benefit (improvement in disability) among stroke patients treated with rt-PA who are randomized to also receive either low-dose Argatroban, high-dose Argatroban or neither."},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["stroke","Argatroban","thrombin-inhibition","thrombolysis","anticoagulation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":90,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Low dose Argatroban + rt-PA (alteplase)","type":"EXPERIMENTAL","description":"100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours\n\nand\n\nrt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour","interventionNames":["Drug: Low Dose Argatroban","Drug: rt-PA (alteplase)"]},{"label":"High dose Argatroban + rt-PA (alteplase)","type":"EXPERIMENTAL","description":"100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours\n\nand\n\nrt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour","interventionNames":["Drug: High Dose Argatroban","Drug: rt-PA (alteplase)"]},{"label":"rt-PA (alteplase)","type":"ACTIVE_COMPARATOR","description":"rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour","interventionNames":["Drug: rt-PA (alteplase)"]}],"interventions":[{"type":"DRUG","name":"Low Dose Argatroban","description":"100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour","armGroupLabels":["Low dose Argatroban + rt-PA (alteplase)"],"otherNames":["Argatroban"]},{"type":"DRUG","name":"High Dose Argatroban","description":"100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour","armGroupLabels":["High dose Argatroban + rt-PA (alteplase)"],"otherNames":["Argatroban"]},{"type":"DRUG","name":"rt-PA (alteplase)","description":"rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour","armGroupLabels":["High dose Argatroban + rt-PA (alteplase)","Low dose Argatroban + rt-PA (alteplase)","rt-PA (alteplase)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With 0 or 1 on Modified Rankin Scale","description":"Excellent functional outcome as measured by the number of patients with a 0 or 1 on the modified Rankin Scale (mRS) at day 90 as assessed by study personnel blinded to treatment.","timeFrame":"90 days"},{"measure":"Number of Participants With Symptomatic Intracranial Hemorrhage Within 48 Hours of tPA Administration","description":"Symptomatic intracranial hemorrhage (sICH) is defined as any evidence of bleeding on CT scan that in the opinion of the treating physician and/or an independent safety monitor is associated with a clinically significant neurological worsening. A four or more point increase in the NIHSS score from baseline (or last score obtained prior to blood found on CT scan) to subsequent CT scan at the time of potential worsening can be used as a guide by the clinical investigator or safety monitor for what represents a significant worsening in neurologic status but sICH can include any worsening deemed significant by the clinical investigator or independent safety monitor.","timeFrame":"48-hours"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Disabling Ischemic stroke symptoms with onset \\< 3 hours treated with IV rt-PA by local standards\\*.\n\n  \\* or ≤ 4.5 hours according to local standard of care.\n* NIHSS ≥ 10\\* or any NIHSS with an intracranial clot should be demonstrated on neurovascular imaging (TCD or CTA) in any one of the following areas: distal internal carotid artery (ICA) carotid artery (CA), middle cerebral artery (MCA - M1 or M2), posterior cerebral artery (PCA - P1 or P2), distal vertebral or basilar artery.\n* TCD criteria: Thrombolysis in brain ischemia (TIBI) 0, 1, 2 or 3 - CT-Angiogram: thrombolysis in myocardial ischemia (TIMI) 0 or 1 \\* NIHSS ≥ 10, demonstration of clot on neuroimaging is not necessary (i.e., enrollment can proceed with non-contrast head CT alone), but if performed, a clot must be demonstrated.\n* For those patients who will undergo repeat CT-Angiogram at 2-3 hours, estimated glomerular filtration rate (eGFR) must be ≥ 60 mL/min/1.73m2.\n* Females of childbearing potential must have a negative serum pregnancy test (HCG) prior to the administration of trial medication.\n* Signed (written) informed consent by the patient or the patient's legal representative and/or guardian.\n\nExclusion Criteria:\n\n* Patients whom the treating physician is planning (or could plan) to treat with intra-arterial thrombolysis or other endovascular procedures (i.e., mechanical clot retrieval) aimed at recanalization.\n* Evidence of intracranial hemorrhage (ICH) on baseline CT scan or diagnosis of a non-vascular cause of neurologic deficit.\n* National institute health stroke scale (NIHSS) Level of Consciousness score (1a) ≥ 2.\n* Pre-existing disability with mRS ≥ 2.\n* CT scan findings of hypoattenuation of the x-ray signal (hypodensity) involving ≥ 1/3 of the MCA territory.\n* Any evidence of clinically significant bleeding, or known coagulopathy.\n* INR \\>1.5.\n* Patients with an elevated activated partial thromboplastin time (aPTT) greater than the upper limit of normal\n* Patients currently, or within the previous 24 hours, on an oral direct thrombin inhibitor (i.e., dabigatran).\n* Heparin flush required for an IV line. Line flushes with saline only.\n* Any history of intra-cranial hemorrhage, known arteriovenous -malformation or unsecured cerebral aneurysms.\n* Significant bleeding episode \\[e.g. gastrointestinal (GI) or urinary tract\\] within the 3 weeks before study enrollment.\n* Major surgery or serious trauma in last 2 weeks.\n* Patients who have had an arterial puncture at a non-compressible site, biopsy of parenchymal organ, or lumbar puncture within the last 2 weeks.\n* Previous stroke, myocardial infarction (MI), post myocardial infarction pericarditis, intracranial surgery, or significant head trauma within 3 months.\n* Uncontrolled hypertension \\[Systolic blood pressure (SBP) \\> 185 mmHg or diastolic blood pressure (DBP) \\>110 mmHg\\] that does not respond to intravenous anti-hypertensive agents.\n* Surgical intervention (any reason) anticipated within the next 48 hours.\n* Known history of clinically significant hepatic dysfunction or liver disease - including a current history of alcohol abuse.\n* Abnormal blood glucose \\<50 mg/dL (2.7 mmol/L).\n* History of primary or metastatic brain tumor.\n* Current platelet count \\< 100,000/mm3.\n* Life expectancy \\< 3 months.\n* Patient who, in the judgment of the investigator, needs to be on concomitant (i.e., during the Argatroban infusion) anticoagulants other than Argatroban, including any form of heparin, unfractionated heparin (UFH), low molecular weight heparin (LMWH), defibrinogenating agent, dextran, other direct thrombin inhibitors or thrombolytic agents, glycoprotein llb/llla (GPIIb/IIIa) inhibitor or warfarin.\n* Participated in any investigational study within 30 days before the first dose of study medication.\n* Known hypersensitivity to Argatroban or its agents.\n* Additional exclusion criteria if patient presents between 3-4.5 hours:\n\n  1. Age \\>80\n  2. Currently taking oral anticoagulants (regardless of INR)\n  3. A history of stroke and diabetes.\n  4. NIHSS \\> 25.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Andrew Barreto, MD","affiliation":"The University of Texas Health Science Center, Houston","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"University of Texas Health Science Center at Houston","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"referencesModule":{"references":[{"pmid":"16908730","type":"BACKGROUND","citation":"Sugg RM, Pary JK, Uchino K, Baraniuk S, Shaltoni HM, Gonzales NR, Mikulik R, Garami Z, Shaw SG, Matherne DE, Moye LA, Alexandrov AV, Grotta JC. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol. 2006 Aug;63(8):1057-62. doi: 10.1001/archneur.63.8.1057."},{"pmid":"22223235","type":"BACKGROUND","citation":"Barreto AD, Alexandrov AV, Lyden P, Lee J, Martin-Schild S, Shen L, Wu TC, Sisson A, Pandurengan R, Chen Z, Rahbar MH, Balucani C, Barlinn K, Sugg RM, Garami Z, Tsivgoulis G, Gonzales NR, Savitz SI, Mikulik R, Demchuk AM, Grotta JC. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke. 2012 Mar;43(3):770-5. doi: 10.1161/STROKEAHA.111.625574. Epub 2012 Jan 5."},{"pmid":"28507269","type":"DERIVED","citation":"Barreto AD, Ford GA, Shen L, Pedroza C, Tyson J, Cai C, Rahbar MH, Grotta JC; ARTSS-2 Investigators. Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke). Stroke. 2017 Jun;48(6):1608-1616. doi: 10.1161/STROKEAHA.117.016720. Epub 2017 May 15."}],"seeAlsoLinks":[{"label":"University of Texas Houston Stroke Team Website","url":"https://med.uth.edu/neurology/specialty-programs/ut-stroke/"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Patients who met the inclusion criteria received a head CT scan prior to initiation of rt-PA and the Argatroban infusion. If available, patients also underwent intracranial vessel imaging performed before or immediately after IV-tPA bolus (but before Argatroban bolus). Patients could not be randomized until after the CTA demonstrated an occlusion.","recruitmentDetails":"Patients who have had an ischemic stroke and admitted to the Accident and Emergency Department or Acute Stroke Unit by their treating physician receive IV Recombinant tissue plasminogen activator as per standard treatment, provided they are able to be treated within 4.5 hours of the onset of their stroke symptoms.","groups":[{"id":"FG000","title":"Low-dose Argatroban + Rt-PA (Alteplase)","description":"100 micrograms/kilogram bolus, followed by 1 micrograms/kilogram/minute IV infusion for 48 hours.\n\nand\n\nIntravenous rt-PA (alteplase) 0.9mg/kg (max dose 90mg); 10% bolus and remaining over 1 hour."},{"id":"FG001","title":"High Dose Argatroban + Rt-PA (Alteplase)","description":"Argatroban: 100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours.\n\nand\n\nIntravenous rt-PA (alteplase) 0.9mg/kg (max dose 90mg); 10% bolus and remaining over 1 hour."},{"id":"FG002","title":"Rt-PA (Alteplase) Only","description":"Intravenous rt-PA (alteplase) 0.9mg/kg (max dose 90mg); 10% bolus and remaining over 1 hour."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"31"},{"groupId":"FG002","numSubjects":"29"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"29"},{"groupId":"FG002","numSubjects":"29"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Patient had hemorrhage after tPA started","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Low Dose Argatroban + Rt-PA","description":"100 micrograms/kilogram bolus, followed by 1 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"},{"id":"BG001","title":"High Dose Argatroban + Rt-PA","description":"100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"},{"id":"BG002","title":"Rt-PA (Alteplase)","description":"rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"90"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"37"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"53"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"70.9","spread":"15.1"},{"groupId":"BG001","value":"67.1","spread":"13.4"},{"groupId":"BG002","value":"68.9","spread":"15.4"},{"groupId":"BG003","value":"68.9","spread":"14.6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"40"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"50"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"65"}]}]},{"title":"United Kingdom","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"25"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With 0 or 1 on Modified Rankin Scale","description":"Excellent functional outcome as measured by the number of patients with a 0 or 1 on the modified Rankin Scale (mRS) at day 90 as assessed by study personnel blinded to treatment.","populationDescription":"One patient in the high dose group did not receive Argatroban and another in the high dose group was lost to follow up; however, an intention-to-treat analysis was used and all 31 enrolled patients were included.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"90 days","groups":[{"id":"OG000","title":"Low Dose Argatroban + Rt-PA","description":"100 micrograms/kilogram bolus, followed by 1 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"},{"id":"OG001","title":"High Dose Argatroban + Rt-PA","description":"100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"},{"id":"OG002","title":"Rt-PA (Alteplase)","description":"rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"29"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Symptomatic Intracranial Hemorrhage Within 48 Hours of tPA Administration","description":"Symptomatic intracranial hemorrhage (sICH) is defined as any evidence of bleeding on CT scan that in the opinion of the treating physician and/or an independent safety monitor is associated with a clinically significant neurological worsening. A four or more point increase in the NIHSS score from baseline (or last score obtained prior to blood found on CT scan) to subsequent CT scan at the time of potential worsening can be used as a guide by the clinical investigator or safety monitor for what represents a significant worsening in neurologic status but sICH can include any worsening deemed significant by the clinical investigator or independent safety monitor.","populationDescription":"One patient in the high dose group did not receive Argatroban and another in the high dose group was lost to follow up; however, an intention-to-treat analysis was used and all 31 enrolled patients were included.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"48-hours","groups":[{"id":"OG000","title":"Low Dose Argatroban + Rt-PA (Alteplase)","description":"100 micrograms/kilogram bolus, followed by 1 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"},{"id":"OG001","title":"High Dose Argatroban + Rt-PA (Alteplase)","description":"100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"},{"id":"OG002","title":"Rt-PA (Alteplase)","description":"rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"29"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Baseline to day 90","description":"AE's regardless of whether thought to be associated with the study or IMP under investigation were graded by the investigator and recorded on the Electronic Case Report Form. An AE form was completed for any intracranial Hemorrhage (ICH). A hemorrhage was labeled as symptomatic by either the local principal investigator of the safety monitor.","eventGroups":[{"id":"EG000","title":"Low Dose Argatroban + Rt-PA","description":"100 micrograms/kilogram bolus, followed by 1 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour","deathsNumAffected":5,"deathsNumAtRisk":30,"seriousNumAffected":15,"seriousNumAtRisk":30,"otherNumAffected":27,"otherNumAtRisk":30},{"id":"EG001","title":"High Dose Argatroban + Rt-PA","description":"100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour","deathsNumAffected":3,"deathsNumAtRisk":31,"seriousNumAffected":15,"seriousNumAtRisk":31,"otherNumAffected":25,"otherNumAtRisk":31},{"id":"EG002","title":"Rt-PA (Alteplase)","description":"rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour","deathsNumAffected":5,"deathsNumAtRisk":29,"seriousNumAffected":14,"seriousNumAtRisk":29,"otherNumAffected":20,"otherNumAtRisk":29}],"seriousEvents":[{"term":"Cardiac Disorders","organSystem":"Cardiac disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Blood and lymphatic system disorders","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Respiratory, thoracic and mediastinal disorders","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":30},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":31},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Nervous system disorders","organSystem":"Nervous system disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"includes: symptomatic intracranial hemorrhage, neurological worsening, cerebral edema/ brain herniation, seizures, etc.","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":30},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":31},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":29}]},{"term":"Electrolyte imbalance","organSystem":"General disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":30},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":31},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":29}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":30},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":31},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":29}]},{"term":"Gastrointestinal disorders","organSystem":"Gastrointestinal disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Renal and Urinary disorders","organSystem":"Renal and urinary disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Skin and subcutaneous tissue disorders","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Musculoskeletal and connective tissue","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Infections and Infestations","organSystem":"Infections and infestations","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29}]}],"otherEvents":[{"term":"Immune system disorders","organSystem":"Immune system disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Dental","organSystem":"General disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Psychiatric disorders","organSystem":"Psychiatric disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Cardiac disorders","organSystem":"Cardiac disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":30},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":31},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":29}]},{"term":"Pulmonary","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":31},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":29}]},{"term":"Electrolyte imbalance","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Blood - circulation system","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Hematologic","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":30},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":31},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":29}]},{"term":"Nervous system disorders","organSystem":"Nervous system disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":30},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":31},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":29}]},{"term":"Ear, Nose and throat (ENT)","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Gastrointestinal disorders","organSystem":"Gastrointestinal disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":30},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":31},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":29}]},{"term":"Genitourinary","organSystem":"Renal and urinary disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Skin and subcutaneous tissue disorders","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":30},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":31},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":29}]},{"term":"Musculoskeletal disorder","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":30},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":31},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Endocrine disorders","organSystem":"Endocrine disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":31},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Metabolism and nutrition disorders","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":30},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":31},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":29}]},{"term":"Infections and infestations","organSystem":"Infections and infestations","sourceVocabulary":"SNOMED CT","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":30},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":31},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":29}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Study limitations include the open-label design that was necessary due to prohibitive costs of placebo manufacture and sham aPTT tests. Given that vessel imaging was not mandatory, a meaningful analysis of early recanalization rates was not possible."},"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Dr. Andrew Barreto","organization":"McGovern Medical School UTHealth - Houston","email":"andrew.d.barreto@uth.tmc.edu","phone":"713-500-7002"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000010959","term":"Tissue Plasminogen Activator"},{"id":"C000031942","term":"Argatroban"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000000925","term":"Anticoagulants"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"}],"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","asFound":"Patient Reported Outcomes","relevance":"HIGH"},{"id":"M16366","name":"Thrombin","relevance":"LOW"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"},{"id":"M57894","name":"Argatroban","asFound":"Legumes","relevance":"HIGH"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":true}